Enanta Pharmaceuticals (ENTA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Company overview and strategic focus

• Heritage in viral infection treatments, notably hepatitis C, with successful commercialization and ongoing royalty revenue.

• Shifted focus from liver viruses to respiratory viruses, including RSV and SARS-CoV-2, identifying unmet needs.

• Initiated a migration into immunology, announcing a KIT inhibitor program for chronic spontaneous urticaria (CSU) earlier this year.

• Plans to expand immunology pipeline with another program announcement later this year.

RSV program updates and clinical milestones

• Pediatric RSV study completed in the Southern Hemisphere; data expected next quarter.

• High-risk adult RSV study ongoing in the Southern Hemisphere, aiming to complete enrollment in the upcoming Northern Hemisphere season.

• Upcoming data readout from a second RSV program (EDP-323) human challenge study expected later this month.

• Zelicapavir, the lead RSV molecule, previously set a high bar in challenge studies and is being further evaluated.

RSV market landscape and treatment rationale

• RSV vaccines have launched for older adults, but uptake remains low and breakthrough infections occur.

• Pediatric prophylaxis relies on passive immunity, leaving a treatment gap as children remain susceptible.

• Antibody resistance is a concern, highlighting the need for effective treatments.

• Company’s RSV approach focuses on replication inhibitors, differing from most competitors targeting viral entry.